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Title 
The impact of institutional clinical trial recruitment versus hospital volume on survival outcomes of 
patients with head and neck cancer: An analysis of the PET-NECK trial outcomes, UKCRN portfolio, 
and Hospital Episode Statistics (HES) in England. 
 
Abstract 
Objectives 
High institutional clinical trial recruitment and high hospital volume are reported to be independent 
indicators of better patient outcomes following cancer treatment. However, their relationship in 
head and neck cancers (HNC) remains less clear. 
Methods 
We aimed to assess the relationship between institutional clinical trial recruitment, hospital 
throughput of HNC cases, and survival of patients with advanced HNC treated with primary 
chemoradiotherapy at hospitals which recruited to the PET-NECK trial (2008-2012). The impact on 
outcome was assessed using Cox’s proportional hazards regression analysis and multivariate 
analysis. 
Results 
HNC RCT recruitment positively correlated with hospital throughput (r=0.57, p<0.0001). Low-
recruiters (1 to 5 patients) had a 107% increased risk of death when compared to high-recruiters (>5 
patients) (HR=2.07, p=0.05). There was no significant impact of hospital throughput on overall or 
disease-specific HNC survival. Multivariate analysis identified p16 status, N-stage, smoking, and RCT 
recruitment volume as the only significant predictors of survival. There was a significant difference in 
chemotherapy regimen between low and high-recruiters (p=0.003) where a higher proportion of 
patients (50%, n=13) in low-recruiting compared to high-recruiting hospitals (29%, n=92) received 
neoadjuvant chemotherapy. A higher proportion of these patients died at low-recruiting hospitals 
(46% versus 23%). 
Discussion 
A significant association exists between high recruitment and better OS for patients with HNC. 
However, no significance was found between hospital throughput and outcomes. The significance of 
individual centre differences in chemotherapy regimen needs further investigation. Future studies 
need a greater number of patient outcome events to support the trends found in this study. 
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Introduction 
Studies have attempted to identify institutional factors that influence the outcome of patients 
undergoing treatment for cancer. The inverse relationship between high hospital volume and lower 
mortality for cancer treatment has been well documented in head and neck (HNC) and other 
cancers.[1–6] More recently, positive outcomes from cancer treatment have also been associated 
with institutional recruitment into clinical trials.[7] Wuthrick et al. demonstrated that institutions 
with high recruitment to clinical trials had a better 5-year overall survival compared to low 
recruitment centres.[7] Patients with HNC who were treated at low recruitment centres had a 91% 
increased risk of death (hazard ratio 1.91).[7] To date however, the mechanisms underlying better 
outcomes at high volume hospitals and high recruitment centres have yet to be elucidated, 
especially whether the association of clinical trials with better outcomes is simply a surrogate for 
centre throughput or is an independent factor. 
We hypothesised that outcomes for HNC are independently associated with recruitment to clinical 
trials, a marker of academic engagement, and not simply a surrogate for institutional patient 
throughput. 
 
Methods 
 
Subjects and databases 
HES data for hospital throughput volume of head and neck cancers 
The number of new patients with HNC treated at hospitals in England from 2007 through 2012 was 
obtained from the NHS England Hospital Episodes Statistics (HES)[8] database using the following 
International Classification of Diseases (ICD-10) codes for head and neck cancers: oral cavity cancer 
excluding inner part of lip and hard palate (C02, C03, C04, C06), oropharynx cancer excluding soft 
palate (C01, C09, C10), nasopharynx cancer (C11), hypopharynx cancer (C12, C13), larynx cancer 
(C32), and palate cancer (C05).[9] The data was reported as the total number of HNC patients seen 
per year at each hospital in England, and an average annual hospital throughput of HNC patients was 
then calculated for 2007 – 2012. 
 
Recruitment to head and neck cancer interventional clinical trials 
Data on recruitment to head and neck clinical trials at all hospitals in England was obtained from the 
UK Clinical Research Network (UKCRN)[10] clinical trials portfolio database for the years 2008 – 
2012, the period of recruitment of the PET-NECK trial. Recruitment data for the years prior to 2008 
were aggregated, and therefore were excluded from the study. Only data on interventional trials 
was included in the statistical analysis. Only data for English hospitals was available, and no data was 
available for hospitals in Scotland, Wales, and Northern Ireland. 
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Patient characteristics and Outcome data from the PET-NECK trial 
The primary and secondary outcomes for this study were overall survival and disease specific 
survival of all patients recruited to the PET-NECK trial (UKCRN ID 3799)[11] at each participating 
hospital respectively. Additional demographic data and characteristics of these patients were also 
obtained and used in the multivariate analysis, including age, gender, smoking status, T-stage, N-
stage, tumour p16 status, and Eastern Cooperative Oncology Group (ECOG) performance status. 
 
Statistical analysis 
Categorisation of hospital throughput 
Cut-offs for recruitment and hospital throughput volumes were determined by identifying the 
tertiles of the whole hospital data. Kaplan-Meier survival curves of low and intermediate versus high 
recruiting hospitals, and conversely low versus intermediate and high hospital throughput groups 
were compared using log-rank tests. Correlation between institutional recruitment and hospital 
throughput was assessed. Multivariate analysis of the determinants of survival was then performed 
by adjusting for age, sex, p16 status, smoking, T-stage, N-stage, ECOG performance status, hospital 
throughput, and institutional recruitment. Proportions of each variable: N-stage, T-stage, 
oropharyngeal, chemotherapy regimen, age, sex, p16 status, ECOG status, and smoking status were 
compared across tertiles for recruitment and hospital throughput to assess for significant differences 
between groups. 
Survival curves were produced using the Kaplan-Meier method. Adjusted analysis of survival and 
multivariate models used Cox’s proportional hazards regression analysis. Tests of differences 
between groups based on count data were by Pearson’s chi-square and where this is for a trend the 
Mantel-Haenszel chi-square was used. Analyses were performed using SAS version 9.3. 
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Results 
Hospital throughput volumes 
A total of 142 hospitals in England submitted HES data on the number of patients with head and 
neck cancers who were treated from 2008 through 2012. The average annual individual hospital 
throughput volume of HNC patients ranged from 0 to 297, with a mean of 49 HNC patients. Low 
throughput hospitals treated an average of less than 20 patients per year, intermediate throughput 
hospitals an average of 20 to 59 per year, and high throughput hospitals an average of 60 or more 
HNC patients per year (Supplementary 1: Figure 1). 
 
Recruitment to interventional head and neck cancer clinical trials 
A total of 96 HNC clinical trials were conducted in England from 2008 – 2012. Of those, 20 were 
interventional trials that completed recruitment between 2008 through 2012. A list of HNC clinical 
trials and reasons for inclusion or exclusion in this study are described in Supplementary 2: Table 1. 
A total of 60 hospitals recruited to the 20 HNC interventional trials from 2008 through 2012. Total 
recruitment per hospital ranged from 1 to 116, with a mean of 21 HNC patients recruited during that 
period. The recruiting hospitals were classified into low, middle, and high-recruiter tertiles with 20 
hospitals in each group (Supplementary 2: Table 2): low-recruiter centres recruited 6 patients or less 
in total between 2008 and 2012, intermediate-recruiters recruited between 7 and 18 patients, and 
high-recruiters recruited 19 or more patients to HNC interventional studies during the specified time 
period (Supplementary 2: Figure 1). 
 
Relationship between hospital throughput and recruitment 
Amongst the hospitals that recruited to the PET-NECK trial, there was a positive association between 
hospital throughput and clinical trial recruitment, where high throughput hospitals tended to have 
higher recruitment to HNC interventional trials, with a Pearson’s correlation of r=0.42 (p<0.0001). 
(Supplementary 3: Figure 1). 
 
Relationship between hospital throughput and survival 
Using the higher tertile cut-off (60 per annum) for hospital throughput, there was no significant 
difference in OS between low (less than 60) and high throughput (>60 cases per year) hospitals 
(p=0.33) (Figure 1 and Supplementary 4: Figure 1) and DSS (p=0.09) (Supplementary 4: Figures 2 and 
3). However, the comparisons appeared to suggest that lower-throughput hospitals had marginally 
better outcomes than higher-throughput hospitals. 
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Relationship between recruitment and survival 
The association between different thresholds of recruitment with OS was then examined using a 
Cox’s proportional hazard model. Patients treated at the lowest tertile of recruiting hospitals (1-6 
patients) appeared to show a trend towards worse OS (HR=1.90, p=0.07, 2-yr OS 69% low vs 86% 
medium and 83% high-recruiters) (Figure 2). If a cut-off of 5 or less was applied, OS was significantly 
worse for low-recruiters (log-rank p=0.0442, Supplementary 5: Figure 1), with a 2-year OS of 66.0% 
(95% C.I. 45.5, 86.6) for centres recruiting between 1 and 5 patients, and a 2-year OS of 83.6%, (95% 
C.I. 80.1, 87.0) for centres recruiting 6 or more patients, with a hazard ratio of 2.07 (p=0.05). No 
significant difference was found between disease specific survival and recruitment volume 
(Supplementary 5: Figure 2). 
Multivariate analysis 
When multivariate analysis was performed, there was a statistically significant association between 
low trial recruitment volume (1-5 patients) and lower overall survival (HR=2.236, 95%CI=1.052 – 
4.754, p=0.0365). Low nodal stage (HR=0.6, p=0.02), never smokers (HR=0.36, p=0.0085), and p16 
negative status (HR=2.91, p<0.0001) were also significantly associated with overall survival. All other 
variables including hospital throughput, age, sex, T-stage, and ECOG did not show a statistically 
significant effect on survival (Table 1). 
Potential causes for differences in survival 
The only statistically significant difference in the characteristics of the three recruitment groups was 
in the chemotherapy schedules used to treat patients (Supplementary 6: Table 21), with a greater 
proportion of patients in low recruiting hospitals (50%, n=13) receiving neoadjuvant chemotherapy 
(TPF) (p=0.003). In the low-recruiter group, 6 out of 13 (46.2%) given docetaxel, platinum, and 5-
fluorouracil (TPF) died; compared to 2 out of 8 (25%) on other chemotherapy regimens (mainly 
concomitant cisplatin) died. In the high-recruiter group, 25 out of 109 (22.9%) given TPF died; and 73 
out of 335 (21.8%) on other chemotherapy regimens died. There were no other significant 
differences in variables across the groups. 
 
Discussion 
There have been several studies establishing positive associations between outcomes and patient 
throughput or trial recruitment. Our study, however, is the first to analyse the relationship of both 
throughput and recruitment into clinical trials with survival, enabling us to explore whether these 
are related or independent predictors of outcome. It confirms the recent finding of a positive 
association between recruitment to interventional studies and improved survival outcomes of HNC 
patients. According to our data, low recruiting centres have a 90% increased risk of death (HR 1.90, 
p=0.05) which is similar to that reported by Wuthrick et al. (HR 1.91). Our study demonstrated 
however that this association appears to be related to the activity of recruiting into clinical trials 
itself, and was not a surrogate for patient throughput of the treating centre, as previously thought 
by Wuthrick et al[7]. 
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Our findings that outcome is related to academic engagement are further supported by the findings 
of Chen et al. that patients treated for advanced stage laryngeal cancer at academic high-volume 
centres had the highest survival rates, more than high-volume non-academic centres[6]. The 
differences in survival demonstrated in our study between high and low recruiting centres appear to 
reflect potential differences in decision-making and in quality of care, and not differences in case 
mix. Patients in low recruitment centres had similar or even slightly more favourable, baseline 
characteristics (e.g. p16+ and ECOG status) than patients in high recruitment centres. Yet, a higher 
proportion of patients in the lower recruitment centres received the more aggressive (TPF) 
treatment regimen, possibly reflecting differences in the quality of decision-making. Clinicians in the 
PET-NECK trial selected chemotherapy schedules from a pre-determined, approved list which 
included neoadjuvant TPF with concomitant chemotherapy. The chemotherapy regimens were 
selected pre-randomisation to the PET-NECK trial and the treatment decisions were made through a 
centralised UK regional multidisciplinary team meeting. More importantly, lower recruitment 
centres had a higher mortality (46% vs 23%) from the more toxic treatment regimen (TPF). This may 
in part be due to lower recruitment centres having less experience, ability or provision to support 
patients through complex interventions and/or to deal with the complications associated with their 
use. These differences may also be a reflection of the nature of clinicians engaging in academic trials, 
and/or of the positive impact of academic engagement on the overall institutional delivery of care to 
patients with HNC[12,13]. Process of care factors at academic institutions need to be further 
investigated to clarify the personnel and resource characteristics of high recruitment centres that 
may have a positive impact on the quality of care delivered at those institutions. 
The reasons for the often-cited relationship between high hospital throughput and better patient 
outcomes have been postulated to be due to differences in the quality and process of care which 
patients receive at high throughput centres, including quality of surgery[1,3,14,15], radiotherapy 
planning and delivery[16], and multi-disciplinary care[17]. Our study demonstrated that after 
adjustment for other factors, there was no independent association between patient throughput 
and survival. However, our study demonstrated a correlation between high throughput and higher 
recruitment into clinical trials, which may explain why previous studies found positive associations 
between patient throughput and outcome.[2,3,6,7,18] 
Limitations 
There is a potential for selection bias in that all institutions studied were involved in recruiting 
patients to the PET-NECK trial. By definition, we could not include hospitals with no trial activity at all 
(‘non-recruiters’) or comment on their outcomes. 
Our hospital volume thresholds were selected post hoc. We accept that this could be criticised as 
arbitrary and that especially the hospitals performing near each threshold boundary may be 
performing at slightly different rates resulting in re-classification to different tertile groups. In the 
absence of a definition of performance thresholds, this approach was necessary to fully explore the 
general trends in performance. However, when analysing by groupings into low versus high 
performers we do not anticipate individual hospitals moving between the two groups to affect our 
final analysis. 
Due to the lack of a defined threshold for low versus high recruitment and hospital throughput, we 
modelled this relationship using Cox’s proportional hazards regression analysis to find the optimal 
Oral Oncology Manuscript Submission – version 19.06.18 
Page 8 of 18 
 
cut-point. Therefore, the arbitrary cut-off between high and low-recruiters set at 5 is unique to our 
data set and requires future studies with matched outcomes to validate this threshold. 
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Figure 1. Kaplan-Meier survival curve of the relationship between hospital throughput and OS 
 
 
Figure 2. Kaplan-Meier survival curve of the relationship between recruitment and OS. (106 events) 
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Table 1. Multivariate analysis 
Parameter  HR 95% C.I. 
Lower 
limit 
95% C.I. 
Upper 
limit 
p-value 
N-stage Low N-stage (1-2)1 0.601  0.393  0.917  0.0182  
T-stage Low T-stage (1-2)1 0.820  0.190  3.546  0.7910  
T-stage High T-stage (3-4)2 1.198  0.280  5.125  0.8071  
Sex Female 1.366  0.785  2.375  0.2695  
Age  1.023  0.996  1.050  0.0917  
p16 Negative 2.912  1.789  4.739  <.0001  
p16 Not known 1.635  0.942  2.838  0.0808  
Throughput 100+ 1.142  0.577  2.260  0.7028  
Throughput 60-100 1.380  0.663  2.871  0.3887  
ECOG  1.450  0.975  2.157  0.0664  
Recruit 1-5 2.236  1.052  4.754  0.0365  
Smoking Current 1.328  0.843  2.091  0.2211  
Smoking Never 0.357  0.166  0.769  0.0085  
 
Supplementary 1: Figure 1. HES data on average annual hospital throughput of HNC patients* by 
hospital trust from 2008 through 2012 
 
*excluding thyroid and salivary gland cancers 
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Supplementary 2: Table 1. UKCRN Head and Neck Cancer Clinical Trials (2008-2012) and 
inclusion/exclusion categories 
  
UKCRN HNC trials in England (2008-2015) UKCRN ID Included (Y/N) RCT (Y/N) Trial design RCT recruiting '08-'12
1 DORA 3832 Yes Yes Randomised Yes
2 NCRN007 Zalute - BSC+/- zalatumumab in SSCHN pts failing platinum chemo 2484 Yes Yes Randomised Yes
3 NCRN013 - SPECTRUM 2675 Yes Yes Randomised Yes
4 NCRN468 MEGHAN - MEHD7945A vs cetuximab in recurrent/metastatic head & neck SCC 13085 Yes Yes Randomised Yes
5 Trismus RfPB trial 13415 Yes Yes Randomised Yes
6 De-ESCALaTE HPV 11723 Yes Yes Randomised  Yes
7 HOPON 4550 Yes Yes Randomised  Yes
8 Lugol's Iodine in Head and Neck Cancer Surgery 9621 Yes Yes Randomised  Yes
9 NCRN153 - EMD 1201081 +Cetuximab in 2nd line,  recurrent / metastatic SCCHN 8153 Yes Yes Randomised  Yes
10 SEND 2069 Yes Yes Randomised  Yes
11 ART DECO 9562 Yes Yes Randomised multicentre Yes
12 COSTAR 5265 Yes Yes Randomised multicentre Yes
13 NCRN291- E7050 +/- Cetuximab in platinum resistant SCCHN 10728 Yes Yes Randomised multicentre Yes
14 PET-NECK study 3799 Yes Yes Randomised multicentre Yes
15 TITAN 10000 Yes Yes Randomised multicentre Yes
16 COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial 13400 Yes Yes Randomised, double-blind, placebo-controlled Yes
17 NCRN206 - LUX-adjuvant Afatinib after chemoradiation in primary unresectable HNC 11522 Yes Yes Randomised, double-blind, placebo-controlled Yes
18 The LEONIDAS2 study 10229 Yes Yes Randomised, double-blind, placebo-controlled Yes
19 NCRN002 - lapatinib and concurrent radiotherapy / cisplatin in stage III, IV SCCHN 2604 Yes Yes Randomised, double-blind, placebo-controlled, multicentre Yes
20 NCRN006 - aadjuvant / maintenance Lapatinib in resected SCCHN 2658 Yes Yes Randomised, double-blind, placebo-controlled, multicentre Yes
21 ARTFORCE Head & Neck (2-arm study) 18545 No Yes Randomised  No
22 CANC - 3417 Phase III Study of MK3475 vs standard treatment in recurrent or metastatic HNC 17352 No Yes Randomised  No
23 CHARTWEL 663 No Yes Randomised  No
24 CompARE Trial 18621 No Yes Randomised  No
25 DAHANCA 21 13565 No Yes Randomised  No
26 NCRN - 3173 CheckMate 141: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 141 16460 No Yes Randomised  No
27 TUBE Trial 16822 No Yes Randomised  No
28 PARSPORT 1283 No Yes Randomised multicentre No
29 PATHOS 18645 No Yes Randomised multicentre No
30 AMG 319 in HPV negative HNSCC 19161 No Yes Randomised, double-blind, placebo-controlled No
31 NCRN583 BKM120 + paclitaxel vs. paclitaxel + placebo 14907 No Yes Randomised, double-blind, placebo-controlled, multicentre No
32 NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer) 16203 No Yes Randomised, placebo-controlled No
33 EaStER Feasibility Study 1503 No Yes Randomised, closed early (incomplete) No
34 IoN 10876 No Yes Thyroid cancer No
35 NCRN131-Sorafenib vs placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Ca 7698 No Yes Thyroid cancer No
36 NCRN319 - E7080 in refractory thyroid cancer 10831 No Yes Thyroid cancer No
37 ElaTION 17373 No Yes Thyroid cancer No
38 'HiLo' 1718 No Yes Thyroid cancer No
39 NCRN087 - XL184 vs placebo in unresectable/metastatic thyroid Ca 7069 No Yes Thyroid cancer No
40 NCRN363: Vandetanib in metastatic medullary thyroid carcinoma 12051 No Yes Thyroid cancer No
41 SIP SMART: Swallowing Intervention package - Self Monitoring, Assessment & Rehabilitation Training 17043 No No Qualitative -
42 Resources for Living (R4L) Pilot 16705 No No Qualitative -
43 Pain: screen and treat 8883 No No Questionnaire study -
44 Quality of life driven consultations in head and neck cancer follow up 8079 No No Questionnaire study -
45 DeteQT 10323 No No Questionnaire study -
46 Determination of Quality of Life Instrument 6082 No No Questionnaire study -
47 Alternative Splicing of Raf Kinases in Cancer 9055 No No Observational -
48 GRAD 19140 No No Observational -
49 HeadandNeck5000 9894 No No Observational -
50 MSCC 9450 No No Observational -
51 NCRN - 2376 Caprelsa in MTC 15014 No No Observational -
52 Do genetic tests help specialists to detect cancer cells? 7493 No No Observational -
53 EORTC Quality of Life Head and Neck Module v4 12850 No No Observational -
54 Exome and protein analysis in HPV associated cancer / pre-cancer 11945 No No Observational -
55 FLAIRE 13992 No No Observational -
56 Head and Neck Cancer: molecular, cellular and immunological mechanisms 8130 No No Observational -
57 A study of biomarkers of senescence in neoplasms of the oral cavity 9854 No No Observational, case-controlled -
58 Genetic factors involved in eyelid mBCC and SGC 14687 No No Observational, case-controlled -
59 After treatment is over: what matters most? 11124 No No Observational, cohort study -
60 Assessing dysphagia and voice in laryngectomy 8600 No No Observational, cohort study -
61 INSIGHT 13860 No No Observational, cohort study -
62 Long-term swallowing outcomes in head and neck cancer 15131 No No Observational, cohort study -
63 PREDICTR-HNC 11317 No No Observational, cohort study -
64 Survivorship in people with oral cancer and their partners 12430 No No Observational, cohort study -
65 Developing a core information set for consent to oral cancer surgery 15348 No No Observational, qualitative -
66 Development of a CBT intervention for dysphagia 15151 No No Observational, qualitative -
67 Home but not Alone 5207 No No Observational, qualitative -
68 Pilot study of CTCAE Toxicity Questionnaires 5995 No No Observational, qualitative -
69 PSQ;H&N 1746 No No Observational, qualitative -
70 SIP2 20259 No No Observational, qualitative -
71 The CONSENSUS Study 13823 No No Observational, qualitative -
72 Imaging Hypoxia in Head & Neck Cancer - A pilot study 14487 No No Safety study -
73 Monitoring of Oral Cancer Patients Using Novel Lab-On-A-Chip Ensembles 7654 No No Safety study -
74 NCRN054 - Zalatumumab+ radiotherapy in locally adv SSCHN not suitable for platinum based chemo 6081 No No Safety study -
75 NCRN362 - Safety of PC-A11 with laser light application in recurrent head & neck SCC 11926 No No Safety study -
76 REALISTIC 11160 No No Safety study -
77 Dielectrophoresis in oral cancer 7073 No No Safety study -
78 ASPOD 6070 No No Safety study -
79 NCRN123 - pemetrexed,cisplatin+ cetuximab in metastatic SSCHN 7695 No No Safety study -
80 A Phase Ib trial of MVAEBNA1/LMP2 vaccine in nasopharyngeal carcinoma 13732 No No Safety study -
81 BoHEMIaN Study 13125 No No Safety study -
82 OCTiLarynx (Optical Coherence Tomography in Larynx) 8939 No No Safety study -
83 QUITS 1.0 13212 No No Safety study -
84 RECaD Larynx 1274 No No Safety study -
85 T4 immunotherapy of head and neck cancer 19183 No No Safety study -
86 VortigERn 7341 No No Safety study -
87 MVA Vaccine Study 5100 No No Safety study -
88 NCRN110 - zalutmumab in non curable SCCHN 8287 No No Safety study -
89 FLT PET to assess tumour proliferation during radical radiotherapy 8495 No No Safety study -
90 PANDORA 13475 No No Safety study -
91 PATRIOT 17568 No No Safety study -
92 TCUK IN 7070 No No Thyroid cancer -
93 EORTC 1209EnTF 18682 No No Thyroid cancer -
94 Assessment of Quality of Life Tools in Medullary Thyroid Cancer (QaLM) 20272 No No Thyroid cancer -
95 Diagnosing thyroid cancer using a blood test 9847 No No Thyroid cancer -
96 THRIFT 15036 No No Thyroid cancer -
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Supplementary 2: Table 2. Grouping of hospitals into tertiles for throughput versus recruitment 
Recruited 
(2008-12) 
Hospital throughput (/yr) 
Low 
(<60) 
Middle 
(60-100) 
High 
(>100) 
Low 
(≤ 6) 
9 5 6 
Middle 
(7-18) 
8 8 4 
High 
(19+) 
2 6 12 
p=0.006 for trend 
 
Supplementary 2: Figure 1. Total recruitment to all HNC interventional trials from 2008 through 
2012 for hospital trusts in England 
 
Total recruitment to all HNC RCTs ranged from 1 to 116 with a mean of 21.27 HNC patients recruited in the 
period from 2008 through 2012. 
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Supplementary 3: Figure 1. Scatterplot of average annual hospital throughput versus clinical trial 
recruitment (2008-2012) 
 
Pearson’s correlation for this association is r=0.42 (p<0.0001) 
 
Supplementary 4: Figure 1. Low versus high hospital throughput and OS 
 
<60 recruited, 2-year OS: 88.3%, 95% CL (80.2, 96.4); 60+ recruited 2-year OS: 81.9%, 95% CL (78.1, 85.7).  
Oral Oncology Manuscript Submission – version 19.06.18 
Page 16 of 18 
 
Supplementary 4: Figure 2. Kaplan-Meier survival curve of the relationship between hospital 
throughput and DSS 
 
 
Supplementary 4: Figure 3. Low versus high hospital throughput and DSS 
 
<60 recruited (5 deaths), 2-year OS: 93.0%, 95% CL (86.5, 99.6); 60+ recruited (74 deaths), 2-year OS: 85.7%, 
95% CL (82.2, 89.2).  
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Supplementary 5: Figure 1. Low versus high recruitment and OS 
 
1 to 5 recruited 2-year OS: 66.0%, 95% C.I. (45.5, 86.6); >5 recruited, 2-year OS: 83.6%, 95% C.I. (80.1, 87.0). 
 
Supplementary 5: Figure 2. Kaplan-Meier survival curve of the relationship between recruitment 
and DSS. (79 events) 
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Supplementary 6: Table 21. Comparison of variables across hospital recruitment tertiles 
 Low (1 to 6) 
n (%) 
Middle (7 to 18) 
n (%) 
High (19+) 
n (%) 
N-stage 1-2 20 (76.9) 100 (81.3) 242 (76.6) 
N-stage 3-4 6 (23.1) 23 (18.7) 74 (23.4) 
    
T-stage 1-2 16 (61.5) 68 (55.3) 184 (58.2) 
T-stage 3-4 10 (38.5) 49 (39.8) 128 (40.5) 
T-stage (occult) 0 (0) 6 (4.9) 4 (1.3) 
    
Oropharyngeal 26 (100) 106 (86.2) 267 (84.5) 
    
Concomitant cisplatin 13 (50.0) 90 (73.2) 185 (58.5) 
TPF 13 (50.0) † 17 (13.8) 92 (29.1) 
Cetuximab 0 (0) 10 (8.1) 17 (5.4) 
Other 0 (0) 6 (4.9) 22 (7.0) 
    
Female 4 (15.4) 24 (19.5) 59 (18.9) 
    
p16 positive 14 (77.8) 69 (70.4) 181 (74.8) 
    
ECOG 0 21 (80.8) 93 (75.6) 251 (79.4) 
ECOG 1 5 (19.2) 29 (23.6) 63 (19.9) 
ECOG 2 0 (0) 1 (0.8) 2 (0.6) 
    
Never smoked 8 (30.8) 32 (26.0) 81 (25.6) 
Past smoker 8 (30.8) 56 (45.5) 149 (47.2) 
Current smoker 10 (38.5) 35 (28.5) 86 (27.2) 
    
Mean age 55.9 59.0 57.8 
Each tertile group is comprised of cases aggregated from 20 hospitals. 
† The proportion of patients in low recruiting hospitals (50%, n=13) receiving neoadjuvant 
chemotherapy (TPF) was significantly different from the other tertiles (p=0.003). There were no 
other significant differences in variables across the groups. 
 
